50th Anniversary and European Expansion
Jiuzhou Pharma marked its 50th anniversary in 2023, commemorating five decades of excellence as an API manufacturer and CDMO service provider in the pharmaceutical industry. To enhance its collaboration with European partners, the company is establishing a new R&D site in Konstanz, Germany. Set to launch in Q1 2025, this facility will focus on delivering cutting-edge solutions in chemical process development. The Konstanz R&D organization is centered around chemistry excellence, a core value that has consistently driven Jiuzhou Pharma’s drug substance development.
Evolving Chemical Development Priorities
Throughout the development lifecycle, the priorities of chemical and analytical development evolve, requiring technical teams to adapt to varying risk mitigation goals. However, scientific excellence remains the foundation of all activities.
Risk Mitigation and API Supply Efficiency
During the early development phase, timely and reliable API supply is critical. The primary objective at this stage is to mitigate risks related to scalability and quality by efficiently building robust process knowledge. To achieve this, Jiuzhou Pharma employs data-rich experimental approaches designed to extract maximum information from each experiment, facilitating a smooth transition to manufacturing. Continuous chemistry, a specialty at Jiuzhou Pharma, offers fast development and scale-up advantages, allowing the company to strategically overcome scalability challenges inherent in batch processes.
Sustainable Manufacturing Focus
Beyond proof-of-concept study supplies, the focus shifts to designing and developing a sustainable, long-term manufacturing process. A crucial early decision in this phase is selecting the synthetic route, which has significant implications for future development, manufacturing, and regulatory activities. Jiuzhou Pharma’s approach to route selection involves extensive idea generation by expert scientists and advanced computational tools.
This is followed by a rigorous route ranking assessment with early input from Jiuzhou’s global procurement team to consider material availability and cost. The company’s expertise in this area provides innovative options to customers, strengthening their IP position and ensuring the success of late-stage clinical candidates by addressing key challenges early on.
Route Scouting and Chemistry Expertise
The most promising ideas then proceed to route scouting, where the goal is to resolve critical disconnections in the process. This phase highlights the importance of synthetic chemistry excellence, as Jiuzhou’s expert scientists generate reliable, high-quality data to inform go/no-go decisions. These efforts are supported by a technology-focused R&D infrastructure that mirrors the company’s manufacturing capabilities, ensuring successful scale-up. Medium- and high-throughput experimentation is essential at this stage, providing valuable screening-level information for reactions, work-ups, and solubility, which influence process design from the outset.
Sustainability in Process Design
Recognizing the industry’s increasing focus on sustainability, Jiuzhou Pharma integrates these considerations into route design and the conceptualization of future industrialization technologies. During process design, attention shifts to optimizing the process and selecting reagents and solvents that contribute to a commercially viable and sustainable outcome.
Applying industry best practices for solvent selection and tracking process metrics
throughout development can significantly impact the overall sustainability
of the process.
At this development stage, establishing a control strategy for impurities requires close collaboration with manufacturing teams and strong support from analytical development.
Advanced Analytical Excellence
Understanding that chemical development cannot succeed without analytical excellence, Jiuzhou Pharma has invested heavily in state-of-the-art instruments to generate high-quality scientific data and provide the necessary expertise to meet any requirements. To maximize the value of this data, the company has implemented a modern electronic lab notebook (ELN) system that integrates laboratory tasks and stores information according to FAIR data principles. All experiments are meticulously documented in English, ensuring the data is readily accessible to customers.
Toni Harsanyi
Head of R&D Germany
Expert Team at Konstanz
The team at Konstanz will be composed primarily of PhD organic chemists with diverse backgrounds and excellent training, enabling them to draw from a wide range of knowledge and experience. The leadership team, deeply involved in strategic and tactical decisions, will leverage decades of process development experience to deliver the best possible outcomes for customers.
